A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs Evofosfamide (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2018 Results of comparison of pharmacokinetic data from MAESTRO trial to that of a phase II (404 study) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, according to a Molecular Templates media release.
    • 16 May 2018 According to a Molecular Templates media release, interim results will be presented at t the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top